NCT00546247 - A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Advanced Solid Tumors

Interventions

DRUG

Epofolate

Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1, 4, 8 and 11 of a 21-day cycle, until the disease progresses

Trial Locations (4)

10021

Memorial Sloan Kettering Cancer Center, New York

19111

Fox Chase Cancer Center, Philadelphia

22057

Lombardi Comprehensive Cancer Center, Washington D.C.

3075 EA

Local Institution, Rotterdam